KR102542555B1 - Cosmetic composition for anti-inflammatory and anti-acne comprising vegetable mucin - Google Patents
Cosmetic composition for anti-inflammatory and anti-acne comprising vegetable mucin Download PDFInfo
- Publication number
- KR102542555B1 KR102542555B1 KR1020220113487A KR20220113487A KR102542555B1 KR 102542555 B1 KR102542555 B1 KR 102542555B1 KR 1020220113487 A KR1020220113487 A KR 1020220113487A KR 20220113487 A KR20220113487 A KR 20220113487A KR 102542555 B1 KR102542555 B1 KR 102542555B1
- Authority
- KR
- South Korea
- Prior art keywords
- mucin
- root
- derived
- cosmetic composition
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 239000002537 cosmetic Substances 0.000 title claims abstract description 23
- 235000013311 vegetables Nutrition 0.000 title abstract description 15
- 230000003110 anti-inflammatory effect Effects 0.000 title abstract description 11
- 230000003255 anti-acne Effects 0.000 title abstract description 4
- 208000002874 Acne Vulgaris Diseases 0.000 claims abstract description 32
- 206010000496 acne Diseases 0.000 claims abstract description 32
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims abstract description 18
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims abstract description 18
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims abstract description 16
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 16
- 239000000284 extract Substances 0.000 claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 claims abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 32
- 240000002853 Nelumbo nucifera Species 0.000 claims description 28
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims description 28
- 235000006576 Althaea officinalis Nutrition 0.000 claims description 23
- 235000003805 Musa ABB Group Nutrition 0.000 claims description 21
- 235000015266 Plantago major Nutrition 0.000 claims description 21
- 235000001035 marshmallow Nutrition 0.000 claims description 20
- 240000004584 Tamarindus indica Species 0.000 claims description 19
- 235000004298 Tamarindus indica Nutrition 0.000 claims description 19
- 241000186427 Cutibacterium acnes Species 0.000 claims description 18
- 235000001591 Pachyrhizus erosus Nutrition 0.000 claims description 17
- 235000018669 Pachyrhizus tuberosus Nutrition 0.000 claims description 17
- 241001307241 Althaea Species 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 244000215747 Pachyrhizus erosus Species 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 5
- 229940055019 propionibacterium acne Drugs 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- 201000004624 Dermatitis Diseases 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 4
- 241000222122 Candida albicans Species 0.000 claims description 3
- 241000191967 Staphylococcus aureus Species 0.000 claims description 3
- 229940095731 candida albicans Drugs 0.000 claims description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- 240000008790 Musa x paradisiaca Species 0.000 claims 5
- 239000001732 althaea officinalis l. extract Substances 0.000 claims 2
- 229940082892 tamarind seed extract Drugs 0.000 claims 2
- 206010040872 skin infection Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 13
- 241000894006 Bacteria Species 0.000 abstract description 10
- 230000002757 inflammatory effect Effects 0.000 abstract description 4
- 102000015728 Mucins Human genes 0.000 description 86
- 108010063954 Mucins Proteins 0.000 description 86
- 230000000052 comparative effect Effects 0.000 description 45
- 241000196324 Embryophyta Species 0.000 description 19
- 241001127637 Plantago Species 0.000 description 16
- 230000005764 inhibitory process Effects 0.000 description 15
- 239000000126 substance Substances 0.000 description 14
- 210000003491 skin Anatomy 0.000 description 12
- 239000000419 plant extract Substances 0.000 description 11
- 239000006210 lotion Substances 0.000 description 10
- 244000258470 Pachyrhizus tuberosus Species 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 244000208874 Althaea officinalis Species 0.000 description 7
- 229940051875 mucins Drugs 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 210000002374 sebum Anatomy 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 208000017520 skin disease Diseases 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 4
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- -1 deoxycycline Natural products 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241001499733 Plantago asiatica Species 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 239000000686 essence Substances 0.000 description 3
- 235000021588 free fatty acids Nutrition 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 2
- 240000008415 Lactuca sativa Species 0.000 description 2
- 240000000982 Malva neglecta Species 0.000 description 2
- 235000000060 Malva neglecta Nutrition 0.000 description 2
- 229920000715 Mucilage Polymers 0.000 description 2
- 244000134552 Plantago ovata Species 0.000 description 2
- 235000003421 Plantago ovata Nutrition 0.000 description 2
- 239000009223 Psyllium Substances 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 229960005280 isotretinoin Drugs 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229940070687 psyllium Drugs 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 235000012045 salad Nutrition 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- SEPPVOUBHWNCAW-FNORWQNLSA-N (E)-4-oxonon-2-enal Chemical compound CCCCCC(=O)\C=C\C=O SEPPVOUBHWNCAW-FNORWQNLSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- LLBZPESJRQGYMB-UHFFFAOYSA-N 4-one Natural products O1C(C(=O)CC)CC(C)C11C2(C)CCC(C3(C)C(C(C)(CO)C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)CO5)OC5C(C(OC6C(C(O)C(O)C(CO)O6)O)C(O)C(CO)O5)OC5C(C(O)C(O)C(C)O5)O)O4)O)CC3)CC3)=C3C2(C)CC1 LLBZPESJRQGYMB-UHFFFAOYSA-N 0.000 description 1
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241001605679 Colotis Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 208000035859 Drug effect increased Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000209477 Nymphaeaceae Species 0.000 description 1
- 241000013557 Plantaginaceae Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- RJWJHRPNHPHBRN-FKVJWERZSA-N aucubin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2C(CO)=C[C@@H](O)[C@@H]2C=CO1 RJWJHRPNHPHBRN-FKVJWERZSA-N 0.000 description 1
- UTDFQMAXCUGNJR-UHFFFAOYSA-N aucubin Natural products OCC1OC(Oc2ccoc2C3C(O)CCC3O)C(O)C(O)C1O UTDFQMAXCUGNJR-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012668 chain scission Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- YVPJCJLMRRTDMQ-UHFFFAOYSA-N ethyl diazoacetate Chemical compound CCOC(=O)C=[N+]=[N-] YVPJCJLMRRTDMQ-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003499 exocrine gland Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002718 inhibitory effect on inflammation Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 235000021109 kimchi Nutrition 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 231100001223 noncarcinogenic Toxicity 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 244000302373 pita floja Species 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 235000020995 raw meat Nutrition 0.000 description 1
- 239000007692 rcm medium Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229940080817 rotenone Drugs 0.000 description 1
- JUVIOZPCNVVQFO-UHFFFAOYSA-N rotenone Natural products O1C2=C3CC(C(C)=C)OC3=CC=C2C(=O)C2C1COC1=C2C=C(OC)C(OC)=C1 JUVIOZPCNVVQFO-UHFFFAOYSA-N 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229940111630 tea tree oil Drugs 0.000 description 1
- 239000010677 tea tree oil Substances 0.000 description 1
- 231100000378 teratogenic Toxicity 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/645—Proteins of vegetable origin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Birds (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
Description
항염증 및 항여드름용 화장료 조성물에 관한 것이다. It relates to a cosmetic composition for anti-inflammatory and anti-acne.
여드름은 피지의 과잉 분비로 인해 모공에 축적되어 염증반응이 나타나는 만성 피부 질환이다(Omer et al., 2017). 대부분 사춘기 청소년 때 발생하는 청소년 질환으로 알려져 있으나, 30~40대 성인에서도 흔히 발생되는 피부질환이다. 젊은 사람(12~24세)의 여드름 발병율은 70~87%이고, 25세~34세 성인의 여드름 발병율은 8%이나, 35세~44세 성인의 3%에서도 여드름이 발생한다(안성구, (2006), 여드름바이블 진단과 치료). 여드름의 직접적인 원인은 남성호르몬으로 알려져 있으며 간접적인 원인으로는 환경오염, 스트레스, 유전, 약물남용, 세균감염 등이 있다. 직접적인 원인으로 알려진 테스토스테론은 피지선을 자극하여 피지분비를 촉진하고, 다량 생산된 피지가 모공벽 각질의 비후를 촉진시키고 이로 인해 모공이 막혀 피지의 배출이 이루어지지 않아 여드름이 발생한다. Acne is a chronic skin disease in which excessive secretion of sebum accumulates in pores and causes an inflammatory response (Omer et al., 2017). Most of them are known as adolescent diseases that occur during puberty, but they are also common skin diseases in adults in their 30s and 40s. The incidence rate of acne among young people (12-24 years old) is 70-87%, and the incidence rate of acne among adults aged 25-34 years is 8%, but acne also occurs in 3% of adults aged 35-44 years (Ahn Seong-gu, ( 2006), acne bible diagnosis and treatment). The direct cause of acne is known as male hormones, and indirect causes include environmental pollution, stress, heredity, drug abuse, and bacterial infection. Testosterone, known as the direct cause, stimulates the sebaceous glands to promote sebum secretion, and the large amount of sebum produced promotes the thickening of dead skin cells on the pore walls, which clogs the pores and prevents the discharge of sebum, resulting in acne.
또한 여드름균으로 알려진 큐티 박테리움 아크네스(Cutibacterium acnes) (2016년 이전 학명은 Propionibacterium acnes)는 혐기성균으로 지방분해효소를 분비하며 이 효소가 피지 중의 중성지방을 분해하여 유리지방산을 형성하는데, 형성된 유리지방산은 피부에 자극을 주게 되어 모낭벽이나 모공 주위의 세포에 염증을 일으킨다. C. acnes는 염증 반응을 유도함으로써 각질형성세포를 자극하여 다량의 활성산소종 (reactive oxygen species, ROS) 을 생성하게 되는데, 이렇게 생성된 활성산소종은 C. acnes 증식 저해 물질의 결핍을 초래하고 피부의 항산화제 파괴, 지질 과산화 반응의 개시, 단백질 및 DNA 산화, 결합조직의 사슬절단 및 비정상적인 교차결합에 의한 주름생성, 멜라닌생성을 유도하여 피부노화를 가속화한다. Also known as acne bacillus , Cutibacterium acnes (scientific name Propionibacterium acnes before 2016) is an anaerobic bacterium that secretes a lipolytic enzyme that breaks down neutral fat in sebum to form free fatty acids. Free fatty acids irritate the skin, causing inflammation in the walls of the hair follicles or cells around the pores. C. acnes stimulates keratinocytes by inducing an inflammatory response to produce a large amount of reactive oxygen species (ROS), which causes a deficiency of substances inhibiting the growth of C. acnes It accelerates skin aging by destroying antioxidants in the skin, initiating lipid peroxidation, oxidizing proteins and DNA, inducing wrinkles and melanin production by chain scission and abnormal cross-linking of connective tissue.
여드름 증상을 호전시킬 수 있는 대표적인 물질로는 테트라사이클린(tetracycline), 디옥시사이클린(doxycycline), 에리트로마이신 (erythromycin)과 같은 항생물질이 있다. 항생물질은 여드름균을 감소시키고, 리파제 활성억제, 유리지방산 생성 감소를 통해 여드름 증상을 완화시킨다. 하지만 지속적인 항생제 사용은 항생제 내성을 야기한다. 이외에도 비타민 A 유도체인 레티노이드, 이소트레티노인, 레티놀은 모낭의 과각화를 억제할 수 있는 물질로 여드름 증상을 개선한다. Representative substances that can improve acne symptoms include antibiotics such as tetracycline, deoxycycline, and erythromycin. Antibiotics alleviate acne symptoms by reducing acne bacteria, inhibiting lipase activity, and reducing free fatty acid production. However, continuous use of antibiotics leads to antibiotic resistance. In addition, retinoids, isotretinoin, and retinol, which are vitamin A derivatives, are substances that can suppress hyperkeratinization of hair follicles and improve acne symptoms.
그러나, 이소트레티노인의 경우 기형을 유발하는 물질로 사용에 주의를 기울여야 한다. 위와 같은 문제를 해결하기 위하여 단일 물질에 비해 상대적으로 부작용이 적은 것으로 알려진 천연물들을 대상으로 광범위하게 여드름 치료물질 탐색이 이루어지고 있다. 이러한 예로 티트리오일, 녹차, 알로에가 있다. 그러나 이러한 식물추출물의 경우 효능을 나타내는 물질의 유효농도가 약하고, 다양한 경로로 촉발되는 여드름 증상에 실제적인 효과를 보여주지 못하고 있는 실정이다. However, care should be taken when using isotretinoin as it is a teratogenic substance. In order to solve the above problems, a wide range of acne treatment substances are being searched for natural products known to have relatively few side effects compared to single substances. Examples of these include tea tree oil, green tea, and aloe. However, in the case of these plant extracts, the effective concentration of substances exhibiting efficacy is weak, and the situation does not show practical effects on acne symptoms triggered by various pathways.
한편으로 뮤신(mucin)이란 동물의 외분비 샘에서 분비되는 점성 물질을 통틀어 이르는 말이며, 당질과 결합된 복합단백질이다. 뮤신은 세포의 주성분인 단백질의 소화를 촉진하여 체내에서 유용한 작용을 하고, 콜레스테롤 저하작용이나 위벽 보호 작용, 해독작용도 한다. 일반적으로, 사람들은 뮤신을 ‘위벽을 보호해주는 물질이라고 생각하지만, 뮤신은 항균작용의 특성을 지니고 있다. 식물성 점액은 일부 미생물을 비롯하여 모든 식물에 존재하는 점도가 높은 고분자 물질로(고분자 다당류 또는 당단백류) 식물성 뮤신(mucin) 또는 뮤실라제(mucilage)라고도 한다. 식물 생태에서의 점액은 식물체내의 물의 이동 및 보존, 전해질과 저분자 물질의 보관 및 이동, 종자의 발아, 상처의 보호 등 여러 가지 역할을 한다. 또한 식물체는 식물성 뮤신과 함께 전해질은 물론 소분자의 2차성 대사물질도 용존 되어 있다. 인공적인 화학 성분이 포함되지 않고, 천연적으로 얻을 수 있는 성분이라는 점에서 식물성 뮤신은 더욱 특별함을 지닌다. On the other hand, mucin refers to all the viscous substances secreted from the exocrine glands of animals, and is a complex protein combined with carbohydrates. Mucin promotes the digestion of protein, which is the main component of cells, and has a useful effect in the body, and also acts to lower cholesterol, protect the stomach wall, and detoxify. Generally, people think of mucin as a substance that protects the gastric wall, but mucin has antibacterial properties. Plant mucus is a high-viscosity polymeric substance (polymer polysaccharide or glycoprotein) present in all plants, including some microorganisms, and is also called vegetable mucin or mucilage. In plant ecology, slime plays various roles such as transporting and preserving water in the plant body, storing and transporting electrolytes and low molecular weight substances, germination of seeds, and protecting wounds. In addition, plants contain not only electrolytes but also dissolved secondary metabolites of small molecules along with plant mucins. Plant mucin is more special in that it does not contain artificial chemical ingredients and is a naturally obtained ingredient.
이러한 배경하에서, 식물 유래 뮤신 또는 뮤신을 함유한 식물추출물 중 여드름균 성장억제효과, 여드름균에 의한 염증억제효과를 보이는 물질을 선별하여 다양한 경로로 발생하는 여드름에 효과적인 치료조성물을 개발하고자 노력하였으며, 그 결과 일 양상을 완성하게 되었다.Under this background, among plant-derived mucins or plant extracts containing mucin, we have tried to develop an effective treatment composition for acne caused by various pathways by selecting substances that exhibit an inhibitory effect on the growth of acne bacteria and an inhibitory effect on inflammation caused by acne bacteria, As a result, the work aspect was completed.
일 양상은 식물성 뮤신 또는 뮤신을 포함하는 식물 추출물을 포함하는 피부 상태 개선용 화장료 조성물을 제공하는 것이다. One aspect is to provide a cosmetic composition for improving skin conditions comprising a plant extract containing a vegetable mucin or mucin.
다른 양상은 식물성 뮤신 또는 뮤신을 포함하는 식물 추출물을 유효성분으로 포함하는 피부 질환의 예방 또는 치료용 약학적 조성물을 제공하는 것이다.Another aspect is to provide a pharmaceutical composition for preventing or treating skin diseases comprising a vegetable mucin or a plant extract containing mucin as an active ingredient.
일 양상은 식물성 뮤신 또는 뮤신을 포함하는 식물 추출물이 함유된 피부 상태 개선용 화장료 조성물을 제공한다. One aspect provides a cosmetic composition for improving skin conditions containing vegetable mucin or a plant extract containing mucin.
본 명세서에서 용어 "화장료 조성물"은 인체를 청결, 미화하여 매력을 더하고 용모를 밝게 변화시키거나 피부의 건강을 유지 또는 증진하기 위하여 인체에 사용되는 물품을 의미한다. In this specification, the term "cosmetic composition" refers to an article used on the human body to clean and beautify the human body to add attractiveness, brighten the appearance, or maintain or promote skin health.
화장료 조성물로 사용되는 경우 유효 성분으로서의 뮤신 또는 뮤신을 함유하는 추출물에 통상적으로 이용되는 성분들을 포함할 수 있다. 이러한 성분들은, 예를 들어 항산화제, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제 및/또는 담체가 있다. 또한 상기 화장료 조성물은 피지 감소 및 여드름 치료, 예방 및 개선 효과를 증진시키기 위하여 피부 흡수 촉진 물질을 추가로 포함할 수 있다.When used as a cosmetic composition, components commonly used in extracts containing mucin or mucin as an active ingredient may be included. These ingredients are conventional adjuvants and/or carriers, such as, for example, antioxidants, stabilizers, solubilizers, vitamins, pigments and flavors. In addition, the cosmetic composition may further include a skin absorption promoting material in order to enhance sebum reduction and acne treatment, prevention and improvement effects.
상기 조성물에 사용된 뮤신은 얌빈뿌리(Pachyrhizus erosus), 연꽃(Nelumbo nucifera)뿌리, 마시멜로(Althaea Officinalis)뿌리, 질경이(Plantago asiatica)씨 및 타마린드(Tarindus indica)씨로부터 얻어질 수 있다.The mucin used in the composition may be obtained from Pachyrhizus erosus , lotus ( Nelumbo nucifera ), marshmallow ( Althaea Officinalis ), plantain ( Plantago asiatica ) and tamarind ( Tarindus indica ) seeds.
상기 식물성 뮤신은 얌빈뿌리 유래 뮤신, 연꽃뿌리 유래 뮤신, 마시멜로뿌리 유래 뮤신, 질경이씨 유래 뮤신 및 타마린드씨 유래 뮤신으로 이루어진 군으로부터 선택된 하나 이상, 둘 이상, 셋 이상 또는 넷 이상의 뮤신 또는 상기 뮤신을 포함하는 식물 추출물일 수 있다. The vegetable mucin is one or more, two or more, three or more or four or more mucins selected from the group consisting of yambean root-derived mucin, lotus root-derived mucin, marshmallow root-derived mucin, plantain seed-derived mucin, and tamarind seed-derived mucin, or the mucin It may be a plant extract containing
예를 들면, 상기 식물성 뮤신은 얌빈뿌리 유래 뮤신, 및 연꽃뿌리 유래 뮤신의 조합, 마시멜로뿌리 유래 뮤신, 질경이씨 유래 뮤신 및 타마린드씨 유래 뮤신의 조합, 얌빈뿌리 유래 뮤신 및 타마린드씨 유래 뮤신의 조합을 포함할 수 있다. For example, the vegetable mucin is a combination of yam bean root-derived mucin and lotus root-derived mucin, marshmallow root-derived mucin, plantain seed-derived mucin and tamarind seed-derived mucin combination, yam bean root-derived mucin and tamarind seed-derived mucin. Combinations may be included.
일 구체예에 있어서, 상기 식물성 뮤신 또는 뮤신을 포함하는 식물 추출물은 얌빈뿌리 유래 뮤신, 연꽃뿌리 유래 뮤신, 마시멜로뿌리 유래 뮤신, 질경이씨 유래 뮤신 및 타마린드씨 유래 뮤신; 또는 상기 뮤신을 포함하는 식물 추출물을 포함할 수 있다. In one embodiment, the plant extract containing the vegetable mucin or mucin is yambin root derived mucin, lotus root derived mucin, marshmallow root derived mucin, plantain seed derived mucin and tamarind seed derived mucin; Alternatively, a plant extract containing the mucin may be included.
본 명세서에서는 여드름 피부의 피부상태 개선에 효능이 있는 물질을 찾고자 항균활성을 갖는 여러 천연물질들 중에서, 여드름 원인균에 대한 우수한 항균 활성을 나타내는 동시에, 여드름 증상을 확대하는 염증반응을 억제하는데 유효한 식물성 뮤신의 조합을 찾아내기 위해 연구하였다. In the present specification, among several natural substances having antibacterial activity in order to find a substance effective for improving the skin condition of acne skin, it exhibits excellent antibacterial activity against acne-causing bacteria and at the same time suppresses the inflammatory reaction that expands acne symptoms. Plant mucin effective A study was conducted to find a combination of
그 결과, 얌빈뿌리(Pachyrhizus erosus), 연꽃(Nelumbo nucifera)뿌리, 마시멜로(Althaea Officinalis)뿌리, 질경이(Plantago asiatica)씨 및 타마린드(Tarindus indica)씨 유래 뮤신을 조합하는 경우, 여드름 원인균에 대한 항균 효과와 항염증효과가 획기적으로 증가함을 발견하였고, 피부에 적용시에도 안전성에 문제가 없음을 확인하였다.As a result, when mucin derived from Yambin root ( Pachyrhizus erosus ), lotus flower ( Nelumbo nucifera ) root, marshmallow ( Althaea Officinalis ) root, plantain ( Plantago asiatica ) seed, and tamarind ( Tarindus indica ) seed was combined, antibacterial activity against acne-causing bacteria It was found that the effect and anti-inflammatory effect increased dramatically, and it was confirmed that there was no problem with safety even when applied to the skin.
상기 추출물의 조합은 얌빈뿌리 유래 뮤신 80 내지 100 중량부, 연꽃뿌리유래 뮤신 20 내지 100중량부, 40 내지 100 중량부, 40 내지 60 중량부, 60 내지 100중량부, 또는 80 내지 100중량부, 마시멜로뿌리 유래 뮤신 80 내지 100 중량부, 질경이씨 유래 뮤신 80 내지 100 중량부, 및 타마린드씨 유래 뮤신 80 내지 100 중량부를 포함할 수 있다.The combination of the extracts is 80 to 100 parts by weight of yambin root-derived mucin, 20 to 100 parts by weight, 40 to 100 parts by weight, 40 to 60 parts by weight, 60 to 100 parts by weight, or 80 to 100 parts by weight of lotus root-derived mucin, 80 to 100 parts by weight of marshmallow root-derived mucin, 80 to 100 parts by weight of plantain seed-derived mucin, and 80 to 100 parts by weight of tamarind seed-derived mucin.
얌빈(Yam bean, Pachyrhizus erosus)은 히카마 또는 멕시코 감자라고도 명명되는 콩과 작물, 덩굴성 구근류이다. 줄기 및 열매에는 독성물질인 로테논이 있어, 구근(뿌리)만 식용 가능하며, 수분이 많고(90%) 탄수화물 및 열량이 낮다. 섬유소, 비타민 C 및 뮤신이 풍부하며, 당수치 억제, 당뇨예방, 체중감량 효과가 있는 이눌린이 함유되어 미국 허핑턴포스트가 선정한 '세계 20대 건강식품'에 선정되었다. 국내에서는 샐러드, 육회, 동치미, 물김치의 요리에 활용된다.Yam bean ( Pachyrhizus erosus ) is a legume, also called jicama or Mexican potato, a climbing bulb. Stems and fruits contain rotenone, a toxic substance, so only the bulbs (roots) are edible, high in moisture (90%) and low in carbohydrates and calories. It is rich in fiber, vitamin C, and mucin, and contains inulin, which is effective in controlling sugar levels, preventing diabetes, and losing weight, and was selected as one of the 'World's Top 20 Health Foods' by The Huffington Post of the United States. In Korea, it is used in salads, raw meat, dongchimi, and water kimchi.
연(蓮)(Nelumbo nucifera)은 수련과에 속하는 다년생 수생(水生)식물로 인도와 중국이 원산지이며 한국, 일본 등에 널리 분포한다. 또한 용도에 있어서 꽃은 관상용과 차제(茶劑)로 이용하고, 잎과 뿌리, 열매는 식용하여 왔다. 연근(蓮根)은 연의 덩이줄기가 땅속으로 비대하여 형성된 것으로, 식이 섬유소가 풍부하여 장내의 활동을 촉진시키고, 당단백질인 뮤신이 함유되어 있어 혈압 강하 및 체내 콜레스테롤 수치를 저하시킨다. 연근에 함유된 탄닌은 각종 출혈증에 효과가 좋으며, 정신안정과 피로회복, 니코틴 해독, 심장병 예방에 효과가 있는 것으로 보고되어 있다.Lotus ( Nelumbo nucifera ) is a perennial aquatic plant belonging to the water lily family, native to India and China, and widely distributed in Korea and Japan. In addition, in terms of use, flowers are used for ornamental purposes and tea preparations, and leaves, roots, and fruits have been eaten. Lotus root (蓮 根) is formed by the tuber of the lotus enlarged into the ground. It is rich in dietary fiber to promote intestinal activity, and contains mucin, a glycoprotein, which lowers blood pressure and cholesterol levels in the body. It is reported that tannin contained in lotus root is effective for various hemorrhages, and is effective for mental stability, fatigue recovery, nicotine detoxification, and prevention of heart disease.
마시멜로(Althaea Officinalis)는 그리스어의 ‘altho(치료한다)’에서 유래된 것으로 식물의 약효에서 비롯됐으며 종명도 약초를 뜻한다. 영명의 ‘marsh’는 습지에서 잘 자라는 상태를, ‘mal-low’는 당아욱을 가르키는 이 허브는, 1.5m씩 자라는 다년초로 내한성이 강하고 잎, 줄기에 비로드 같은 부드러운 솜털이 덮여있다. 잎은 다소 두터우며 하트형으로 크고 얕게 갈라져 있고, 꽃은 7~8월에 줄기 끝에 달린 잎 밑쪽에서 4~5송이씩 2.5㎝ 크기의 핑크색 5판화가 핀다. 동그랗고 납작한 열매가 결실이 되는 마쉬 말로우는 특히 식물전체에 향긋하고 연한 향기가 날 뿐만 아니라 25~30%의 많은 점액이 함유되어 있다. 예부터 약초로 쓰여 온 귀중한 식물의 하나로, 약효가 뛰어나 고대 아랍인들도 소염제로서 도포제로 잎을 이용했다. 또한 잎과 뿌리를 샐러드로 이용해 끈적이면서 감미로운 맛을 즐겼다.Marshmallow ( Althaea Officinalis ) is derived from the Greek word 'altho' (to treat), which is derived from the medicinal properties of plants, and the species name also means medicinal herbs. In the English name, 'marsh' refers to a state that grows well in wetlands, and 'mal-low' refers to mallow. This herb is a perennial plant that grows 1.5m tall, has strong cold resistance, and its leaves and stems are covered with soft downy hairs like velvet. Leaves are rather thick, heart-shaped, large and shallowly divided. Flowers bloom in July-August in pink 5-pieces of 2.5 cm in size, 4-5 at the bottom of the leaf at the end of the stem. Marshmallow, which produces round and flat fruits, has a particularly fragrant and light scent throughout the plant and contains 25-30% of mucus. It is one of the precious plants that have been used as medicinal herbs since ancient times, and the ancient Arabs also used the leaves as a liniment as an anti-inflammatory because of its excellent medicinal properties. In addition, the leaves and roots were used as a salad and enjoyed the sticky and sweet taste.
질경이(Plantago asiatica)는 질경이과(Plantaginaceae)에 속하는 다년생 초본으로 어린잎은 식용한다. 한방에서는 뿌리채 뽑아 말려서 차전초(車前草)라 하고, 종자를 차전자(車前子)라는 약재로 사용하고, 한국, 일본, 사할린, 타이완, 중국, 시베리아, 동부 히말라야, 자바, 말레이시아 등지에 분포한다. 차전자피는 질경이 씨 껍질로써 점액을 형성하는 성분을 다량 함유하여 수분 보유량이 뛰어난 식품이다. 다량의 점액질 외에 지방질, 어쿠빈(aucubin), 갈락타(galacta), 폴리사카라이드(polysaccaharide), 숙신산(succinic acid) 등이 있다. Plantago asiatica is a perennial herb belonging to the Plantaginaceae family, and its young leaves are edible. In oriental medicine, it is called chajeoncho (車前草) by pulling out the roots and drying them, and the seeds are used as a medicinal material called psyllium, and are distributed in Korea, Japan, Sakhalin, Taiwan, China, Siberia, the Eastern Himalayas, Java, Malaysia, etc. . Psyllium hull is a plantain seed husk that contains a large amount of mucus-forming ingredients and is a food with excellent water retention. In addition to a large amount of mucilage, there are lipids, aucubin, galacta, polysaccharide, and succinic acid.
타마린드(Tarindus indica)는 콩과의 상록교목으로서 북아프리카 원산이며 인도에서 수세기동안 재배되어왔다. 17세기에 스페인 정복자들에 의해 멕시코로 전해졌으며 지금은 카리브해 지역, 동남 아시아, 중국 등 전세계 열대지역에서 재배되고 있다. 타마린드의 종자에서 추출한 다당류는 실처럼 늘어지는 성질이 적고 끈적임이 적어 생체 적합성, 비발암성 및 열과 pH에 안정하기 때문에 식품에서는 증점제 및 안정제 용도로 사용되며, 제약에서는 다양한 약제학적 부형제로 사용된다. 화장품에서는 발림성 개선제로 이용되고 있다.Tamarind ( Tarindus indica ) is an evergreen tree native to North Africa and has been cultivated in India for centuries. It was brought to Mexico by Spanish conquistadors in the 17th century and is now cultivated in tropical regions around the world, including the Caribbean, Southeast Asia, and China. Polysaccharides extracted from tamarind seeds are biocompatible, non-carcinogenic, and stable against heat and pH, with little stringiness and low stickiness, so they are used as thickeners and stabilizers in foods and as various pharmaceutical excipients in pharmaceuticals. In cosmetics, it is used as an applicability improver.
상기 뮤신을 식물에서 추출하는 경우, 추출 및 공정 용매로 물, 탄소수 1 내지 5의 알코올, 헥산, 클로로포름, 부틸렌 글리콜 (Butylene glycol) 또는 이들의 혼합용매로 추출 또는 정제된 것을 사용하는 것이 바람직하나, 반드시 이로 제한되지는 않는다.When the mucin is extracted from plants, it is preferable to use water, alcohol having 1 to 5 carbon atoms, hexane, chloroform, butylene glycol, or a mixed solvent extracted or purified as an extraction and process solvent. , but is not necessarily limited thereto.
또한, 상기 뮤신은 상기 용매에 의하여 추출, 정제하는 방법 외에 통상적인 정제 과정을 거쳐서도 수득할 수 있다. 예컨대, 일정한 분자량 컷-오프 값을 갖는 한외여과막을 이용한 분리, 다양한 크로마토그래피(크리, 전하, 소수성 또는 친화성에 따른 분리를 위해 제작된 것)에 의한 분리와 같이, 추가적으로 실시된 다양한 정제 방법을 통해 얻어진 분획을 통하여도 뮤신을 수득할 수 있다.In addition, the mucin can be obtained through a conventional purification process in addition to extraction and purification using the solvent. Through various additional purification methods, such as, for example, separation using ultrafiltration membranes with a certain molecular weight cut-off value, separation by various chromatography (designed for separation according to cree, charge, hydrophobicity or affinity). Mucin can also be obtained through the obtained fraction.
본 명세서에서는 얌빈뿌리, 연꽃뿌리, 마시멜로뿌리, 질경이씨 및 타마린드씨 유래 뮤신의 복합물을 제조하여 이를 다양한 중량비로 구성하여 항균효과와 항염증 효과 실험을 진행하였다.In the present specification, mucin complexes derived from yam bean root, lotus root, marshmallow root, plantain seed, and tamarind seed were prepared and configured at various weight ratios to test antibacterial and anti-inflammatory effects.
일 구체예에 있어서, 상기 조성물은 NO(nitric oxide) 생성 억제 또는 TNF-α 발현을 억제하는 것일 수 있다. In one embodiment, the composition may inhibit NO (nitric oxide) production or TNF-α expression.
본 명세서에서 상기 피부 여드름균은 예를 들면 캔디다 알비칸(Candida albicans), 프로피오니박테리움 아크네스(Propionibacterium acnes), 스타필로코커스 아우레스(Staphylococcus aureus) 및 큐티박테리움 아크네스(Cutibacterium acnes) 로 이루어진 군으로부터 선택된 1종 이상일 수 있다. In the present specification, the skin acne bacteria are, for example , Candida albicans, Propionibacterium acnes, Staphylococcus aureus and Cutibacterium acnes. It may be one or more selected from the group consisting of
또 하나의 구체적 실시에서, 일 양상의 뮤신 또는 뮤신을 함유하는 상기 조성물은 큐티박테리움 아크니스(Cutibacterium acnes)에 대한 항균 활성 또는 항산화 활성을 가진 것이 확인되었다. In another specific embodiment, it was confirmed that the mucin or the composition containing the mucin of one aspect has antibacterial activity or antioxidant activity against Cutibacterium acnes .
따라서, 일 양상의 식물성 뮤신 또는 뮤신을 함유하는 추출물은 일 양상의 목적인 여드름성 피부 개선을 위하여 유용하게 사용할 수 있다.Therefore, one aspect of the vegetable mucin or an extract containing mucin can be usefully used for improving acne-prone skin, which is the object of one aspect.
상기 조성물은 유효 성분으로 식물성 뮤신 또는 뮤신을 포함하는 추출물을 전체 조성물의 중량을 기준으로 0.001 내지 10 중량%, 바람직하게 0.01 내지 10중량%, 보다 바람직하게는 0.1 내지 10중량%로 함유할 수 있다. 함량이 0.001% 미만인 경우에는 항염 및 여드름 개선 효과가 너무 미약하고, 15 중량%를 초과하는 경우에는 함량의 증가에 따른 효과의 증가가 미비하고 제형상의 안정성이 확보되지 않는 문제점이 있다.The composition may contain vegetable mucin or an extract containing mucin as an active ingredient in an amount of 0.001 to 10% by weight, preferably 0.01 to 10% by weight, more preferably 0.1 to 10% by weight based on the total weight of the composition. . If the content is less than 0.001%, the anti-inflammatory and acne-reducing effect is too weak, and if it exceeds 15% by weight, the increase in the effect due to the increase in the content is insufficient and the stability of the formulation is not secured.
상기 화장료 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있다. 이러한 제형은, 예를 들어, 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클린싱, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이 등으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 보다 상세하게는, 화장수, 스킨, 스킨소프너, 스킨토너, 아스트린젠트, 로션, 밀크로션, 모이스쳐 로션, 영양 로션, 마사지크림, 영양 크림, 모이스쳐 크림, 핸드크림, 손세정제, 파운데이션, 에센스, 영양 에센스, 팩, 비누, 클렌징폼, 클렌징로션, 클렌징크림, 바디로션, 바디클렌저, 현탁액, 겔, 분말, 페이스트, 마스크팩, 및 시트로 이루어지는 군으로부터 선택되는 하나의 제형으로 제조될 수 있다.The cosmetic composition may be prepared in any formulation conventionally prepared in the art. Such formulations are formulated into, for example, solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansers, oils, powder foundations, emulsion foundations, wax foundations and sprays, and the like. It may be, but is not limited thereto. More specifically, lotion, toner, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nutrient lotion, massage cream, nutrient cream, moisture cream, hand cream, hand sanitizer, foundation, essence, nutrient essence, It can be prepared as one formulation selected from the group consisting of packs, soaps, cleansing foams, cleansing lotions, cleansing creams, body lotions, body cleansers, suspensions, gels, powders, pastes, mask packs, and sheets.
다른 양상은 식물성 뮤신 또는 뮤신을 포함하는 식물 추출물을 유효성분으로 포함하는 피부 질환의 예방 또는 치료용 약학적 조성물을 제공한다. Another aspect provides a pharmaceutical composition for preventing or treating skin diseases comprising a vegetable mucin or a plant extract containing mucin as an active ingredient.
상기 식물 뮤신 또는 뮤신을 포함하는 식물 추출물에 대해서는 상기한 바와 같다. The plant mucin or plant extract containing the mucin is as described above.
상기 피부 질환은 피부 염증으로 인한 질환일 수 있고, 예를 들어, 피부염, 아토피 피부염, 알레르기성 피부염, 지루성 피부염, 건선, 여드름을 포함할 수 있으나, 이에 제한되는 것은 아니다.The skin disease may be a disease caused by skin inflammation, and may include, for example, dermatitis, atopic dermatitis, allergic dermatitis, seborrheic dermatitis, psoriasis, and acne, but is not limited thereto.
용어 "예방"은 질병의 발생을 억제하는 것을 포함한다.The term "prevention" includes inhibiting the development of a disease.
용어 "치료"는 질병의 발전의 억제, 경감 또는 제거를 포함한다.The term "treatment" includes the inhibition, alleviation or elimination of the development of a disease.
상기 약학적 조성물은, 추가로 약학적으로 허용 가능한 담체를 1종 이상 포함하여 제조할 수 있다. 약학적으로 허용 가능한 담체는 식염수, 멸균수, 링거액, 완충 식염수, 덱스트로오스 용액, 말토덱스트린 용액, 글리세롤, 에탄올 및 이들 성분 중 1 성분 이상을 혼합하여 사용할 수 있으며, 필요에 따라 항산화제, 완충액, 정균제 등 다른 통상의 첨가제를 첨가할 수 있다. The pharmaceutical composition may be prepared by further including one or more pharmaceutically acceptable carriers. A pharmaceutically acceptable carrier may be a mixture of saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol, and one or more of these components, and, if necessary, antioxidants and buffers. , bacteriostatic agents and other conventional additives may be added.
또한, 희석제, 분산제, 계면활성제, 결합제 및 윤활제를 부가적으로 첨가하여 수용액, 현탁액, 유탁액과 같은 주사용 제형, 환약, 캡슐, 과립 또는 정제로 제제화할 수 있다. 더 나아가 당 분야의 적정한 방법으로, 각 질환에 따라 또는 성분에 따라 바람직하게 제제화할 수 있다.In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to prepare formulations for injection such as aqueous solutions, suspensions, and emulsions, pills, capsules, granules, or tablets. Furthermore, it can be preferably formulated according to each disease or component by an appropriate method in the art.
상기 약학적 조성물은 식물성 뮤신 또는 뮤신을 포함하는 식물 추출물과 함께 항염증 효과를 갖는 공지의 유효성분을 1종 이상 함유할 수 있다.The pharmaceutical composition may contain at least one known active ingredient having an anti-inflammatory effect together with a vegetable mucin or a plant extract containing mucin.
상기 약학적 조성물은 목적하는 방법에 따라 경구 투여하거나 비경구 투여(예를 들어, 정맥 내, 피하, 복강 내 또는 국소에 적용)할 수 있으며, 투여량은 환자의 체중, 연령, 성별, 건강상태, 식이, 투여시간, 투여방법, 배설율 및 질환의 중증도 등에 따라 그 범위가 다양하다. 상기 조성물의 일일 투여량은 약 0.0001~500 mg/kg, 바람직하게는 약 0.001~300 mg/kg이며, 하루 일회 내지 수회에 나누어 투여하는 것이 바람직하다.The pharmaceutical composition may be administered orally or parenterally (for example, intravenously, subcutaneously, intraperitoneally or topically applied) according to the desired method, and the dosage is determined according to the patient's weight, age, sex, and health condition. , the range varies depending on the diet, administration time, administration method, excretion rate, and severity of the disease. The daily dose of the composition is about 0.0001 to 500 mg/kg, preferably about 0.001 to 300 mg/kg, and it is preferable to divide the administration once or several times a day.
일 양상에 따른 식물성 뮤신 또는 식물성 뮤신을 포함하는 추출물은 여드름 균에 대한 항균효과, NO 생성 및 염증매개인자인 TNF-α 발현 억제 활성을 가져 피부 상태 개선용 화장료 조성물 또는 약학적 조성물에 유용하게 이용될 수 있는 효과가 있다. Plant mucins or extracts containing plant mucins according to one aspect have antibacterial effects against acne bacteria, NO production, and inhibitory activity of TNF-α expression, which is an inflammatory mediator, so that they are useful in cosmetic compositions or pharmaceutical compositions for improving skin conditions There is an effect that can be.
일 양상에 따르면 상기 화장료 조성물은 여드름균인 프로피오니박테리움아크네(Propionibacterium acnes)균의 성장을 억제하는 뛰어난 효과가 있다. According to one aspect, the cosmetic composition has an excellent effect of inhibiting the growth of acne bacteria, Propionibacterium acnes .
일 양상에 따라 제조된 상기 추출물을 유효성분으로 함유하는 화장료 조성물은 당 업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예컨대 화장수, 로션, 크림 및 에센스로 제형화할 수 있다.The cosmetic composition containing the extract prepared according to one aspect as an active ingredient may be prepared in any formulation commonly prepared in the art, such as lotion, lotion, cream and essence.
이하, 실시예, 비교예 및 실험예를 통하여 보다 상세하게 설명한다. 이는 일 양상이 속하는 기술분야에서 통상의 지식을 가진 자가 발명을 용이하게 실사할 수 있을 정도로 상세하게 설명하기 위한 것이지, 이로 인해 일 양상의 기술적인 사상 및 범주가 한정되는 것을 의미하지는 않는다.Hereinafter, it will be described in more detail through Examples, Comparative Examples and Experimental Examples. This is to explain the invention in detail to the extent that a person skilled in the art can easily inspect the invention, but does not mean that the technical spirit and scope of the aspect are limited.
제조예 1 : 식물성 뮤신의 제조Preparation Example 1: Preparation of vegetable mucin
건조된 얌빈뿌리 100g을 분쇄한 후 3L의 10% EtOH을 사용하여 12시간 가온 추출한 후, 냉침 시키고, 1㎛ 투과 사이즈를 갖는 여과지로 여과하여 여과액을 수득하였다. 수득된 여과액을 감압농축하여 10배의 농축액을 얻는다. 농축액에 3배의 EtOH를 넣어 실온에서 침강의 과정을 거친다. 원심분리 또는 여과과정을 통하여 침전부분만 회수하여 열풍건조, 진공건조 또는 동결건조 과정을 거쳐 식물유래 뮤신을 제조하였다.After pulverizing 100 g of the dried yam bean root, it was heated and extracted with 3 L of 10% EtOH for 12 hours, cooled, and filtered through a filter paper having a 1 μm permeation size to obtain a filtrate. The obtained filtrate was concentrated under reduced pressure to obtain a 10-fold concentrated solution. Three times the amount of EtOH is added to the concentrated solution and sedimentation is performed at room temperature. Plant-derived mucin was prepared by recovering only the precipitated portion through centrifugation or filtration, followed by hot air drying, vacuum drying, or freeze drying.
상기와 동일한 방법으로 각각 연꽃뿌리, 마시멜로뿌리, 질경이씨 및 타마린드씨의 건조 분말을 제조하였다.Dry powders of lotus root, marshmallow root, plantain seed, and tamarind seed were prepared in the same manner as above.
실시예 및 비교예의 조성: 얌빈뿌리, 연꽃뿌리, 마시멜로뿌리, 질경이씨 및 타마린드씨 유래 뮤신의 복합물의 제조Compositions of Examples and Comparative Examples: Preparation of mucin complexes derived from yambin root, lotus root, marshmallow root, plantain seed and tamarind seed
얌빈뿌리, 연꽃뿌리, 마시멜로뿌리, 질경이씨 및 타마린드씨 유래 뮤신을 함유하는 혼합물을 하기 표 1, 표 2의 조성으로 제조하였다. 구체적으로, 하기 표 1, 2의 조성으로 각각의 복합물을 혼합하고, 복합물을 멸균 처리(KRS A-1, Health up, Korea)된 용기에 옮겨 담아 5℃에서 냉장보관하였다. A mixture containing mucin derived from yam bean root, lotus root, marshmallow root, plantain seed and tamarind seed was prepared according to the compositions shown in Tables 1 and 2 below. Specifically, each composite was mixed with the composition shown in Tables 1 and 2 below, and the composite was transferred to a sterilized container (KRS A-1, Health up, Korea) and stored in a refrigerator at 5°C.
실험예 1: NO 생성 억제Experimental Example 1: Inhibition of NO production
얌빈뿌리, 연꽃뿌리, 마시멜로뿌리, 질경이씨 및 타마린드씨 유래 뮤신의 항염증 효과를 알아보기 위해 NO 생성 억제 효과를 확인하였다. 마우스 대식 세포인 RAW 264.7 세포를 2 X 106 cells/dish density로 60mm 플레이트(plate)에 분주하여 24시간 동안 플레이트에서 배양하였다. 염증반응을 유발하기 위해 1㎍/㎖ 농도의 LPS(lipopolysaccharide)와 시험물질을 함유한 새로운 배지를 처리하여 24시간 배양하였다. NO assay를 통한 항염 활성 평가는 griess A, B reagent를 이용한 방법으로, 1% sulfanilamide, 0.1% N-(1-naphtyl)ethylenediamine dihydrochloride reagent를 1:1 비율로 혼합하여 사용하였다. 본 실험예에서는 상기 실시예 1, 실시예 2-1 내지 2-4, 및 비교예 1 내지 8에 대해 모두 500 ug/ml의 농도로 동일하게 처리하였다. 96 well plate에서 실시예 1, 실시예 2-1 내지 2-4 및 비교예 1 내지 8를 처리 후 37℃ 5% CO2의 조건에서 24시간 동안 배양된 배지의 상등액을 griess (A+B) reagent와 1:1 비율로 각각 50㎕씩 혼합하여 10분간 상온에서 보관한 후 540nm에서 ELISA 측정을 통해 NO 생성 억제능을 측정하였다. 그 결과는 하기 표 4, 표 5에 나타내었다. NO 생성 억제율 (%)은 대조군(100 %)을 기준으로 NO 생성률 (%)을 100 %에서 뺀 값을 말한다.In order to investigate the anti-inflammatory effect of mucins derived from yam bean root, lotus root, marshmallow root, plantain seed, and tamarind seed, the NO production inhibitory effect was confirmed. RAW 264.7 cells, which are mouse macrophages, were dispensed into a 60 mm plate at a density of 2 X 10 6 cells/dish and cultured in the plate for 24 hours. In order to induce an inflammatory reaction, a new medium containing LPS (lipopolysaccharide) at a concentration of 1 μg/ml and a test substance was treated and cultured for 24 hours. Anti-inflammatory activity evaluation through NO assay was performed using griess A and B reagents, mixing 1% sulfanilamide and 0.1% N-(1-naphtyl)ethylenediamine dihydrochloride reagent in a 1:1 ratio. In this experimental example, all of Example 1, Examples 2-1 to 2-4, and Comparative Examples 1 to 8 were treated the same at a concentration of 500 ug/ml. After processing Example 1, Examples 2-1 to 2-4, and Comparative Examples 1 to 8 in a 96-well plate, the supernatant of the cultured medium for 24 hours at 37 ° C. 5% CO 2 griess (A + B) After mixing 50 μl of each with the reagent at a 1:1 ratio and storing at room temperature for 10 minutes, the NO production inhibitory ability was measured by ELISA measurement at 540 nm. The results are shown in Tables 4 and 5 below. The NO production inhibition rate (%) refers to the value obtained by subtracting the NO production rate (%) from 100% based on the control group (100%).
구분
division
상기 표 4와 표 5에 나타난 바와 같이, 실시예 2-1 내지 2-4의 샘플은 모두 비교예 1 내지 8 대비 NO 생성 억제율이 현저히 향상되는 것으로 나타났다. 구체적으로, 비교예 2 및 비교예 8의 NO 생성 억제율을 기준으로 콜비식 (Colby's equation) 예측치를 계산하면, 44.9%가 나오는데, 실시예 2-1 내지 2-4의 실측치는 모두 콜비식 예측치를 상회하는 결과를 나타내어 상승효과가 나타남을 확인하였다. 특히, 실시예 2-2 내지 2-3의 샘플은 NO 생성 억제율이 현저히 높게 나타났다.As shown in Table 4 and Table 5, the samples of Examples 2-1 to 2-4 were all significantly improved in NO production inhibition rate compared to Comparative Examples 1 to 8. Specifically, when the predicted value of Colby's equation is calculated based on the NO production inhibition rate of Comparative Example 2 and Comparative Example 8, 44.9% is obtained. It was confirmed that the synergistic effect appeared by showing the result exceeding. In particular, the samples of Examples 2-2 to 2-3 exhibited a remarkably high NO production inhibition rate.
실험예 2: 염증성 사이토카인 TNF-α 발현 억제 효능 확인Experimental Example 2: Confirmation of inhibitory effect on the expression of inflammatory cytokine TNF-α
얌빈뿌리, 연꽃뿌리, 마시멜로뿌리, 질경이씨 및 타마린드씨 유래 뮤신의 항염증 효과를 알아보기 위해 염증성 사이토카인 TNF-α의 발현 억제효과를 확인하였다. 마우스 대식세포인 RAW 264.7 세포를 10% FBS가 첨가된 DMEM 배지를 이용하여 5Х105 cell/well로 조절한 후, 12 well plate에 접종하고 18시간 동안 배양하였다. 본 실험예에서는 상기 실시예 1, 실시예 2-1 내지 2-4, 및 비교예 1 내지 8에 대해 모두 500 ug/ml의 농도로 동일하게 처리하였다. 배양한 뒤 12시간 동안 기아상태를 유지시킨 후, LPS 10ng/mL와 실시예 1, 실시예 2-1 내지 2-4 및 비교예 1 내지 8을 처리하고 24시간 동안 배양하였다. 배양된 세포에서 RNA를 추출하여 Reverse transcription polymerase chain reaction(RT-PCR)을 통해 TNF-α의 발현율을 확인하였다. TNF-α 발현율은 하기 수학식 1에 의해 산출되었고, TNF-α 발현 억제율은 100 %에서 TNF-α 발현율을 뺀 값을 말한다. 그 결과는 하기 표 6과 표 7에 나타내었다. In order to investigate the anti-inflammatory effect of mucins derived from yam bean root, lotus root, marshmallow root, plantain seed and tamarind seed, the inhibitory effect on the expression of the inflammatory cytokine TNF-α was confirmed. Mouse macrophage RAW 264.7 cells were adjusted to 5Х10 5 cells/well using DMEM medium supplemented with 10% FBS, and then inoculated into a 12 well plate and cultured for 18 hours. In this experimental example, all of Example 1, Examples 2-1 to 2-4, and Comparative Examples 1 to 8 were treated the same at a concentration of 500 ug/ml. After culturing and maintaining a starvation state for 12 hours, LPS 10ng / mL and Example 1, Examples 2-1 to 2-4 and Comparative Examples 1 to 8 were treated and cultured for 24 hours. RNA was extracted from cultured cells and the expression rate of TNF-α was confirmed through reverse transcription polymerase chain reaction (RT-PCR). The TNF-α expression rate was calculated by Equation 1 below, and the TNF-α expression inhibition rate refers to a value obtained by subtracting the TNF-α expression rate from 100%. The results are shown in Tables 6 and 7 below.
[수학식 1][Equation 1]
TNF-α 발현율(%)=(시료 TNF-α 발현양/대조군 TNF-α 발현양)Х100TNF-α expression rate (%) = (sample TNF-α expression level/control group TNF-α expression level) Х100
상기 표 6과 표 7에 나타난 바와 같이, 실시예 2-1 내지 2-4의 샘플은 모두 비교예 1 내지 8 대비 TNF-α 발현 억제율이 현저히 향상되는 것으로 나타났다. 구체적으로, 비교예 2 및 비교예 8의 TNF-α 발현 억제율을 기준으로 콜 비식(Colby's equation) 예측치를 계산하면, 51.5%가 나오는데, 실시예 2-1 내지 2-4의 실측치는 모두 콜비식 예측치를 상회하는 결과를 나타내어 상승효과가 나타남을 확인하였다. 특히, 실시예 2-2 내지 2-3의 샘플은 TNF-α 발현 억제율이 현저히 높게 나타났다.As shown in Tables 6 and 7 above, the samples of Examples 2-1 to 2-4 showed significantly improved inhibition of TNF-α expression compared to Comparative Examples 1 to 8. Specifically, when calculating the predicted value of Colby's equation based on the TNF-α expression inhibition rate of Comparative Example 2 and Comparative Example 8, 51.5% is obtained, and the actual values of Examples 2-1 to 2-4 are all Colby's equation It was confirmed that the synergistic effect appeared as the result exceeded the predicted value. In particular, the samples of Examples 2-2 to 2-3 showed a remarkably high rate of inhibition of TNF-α expression.
실험예 3: 복합물의 큐티 박테리움 아크네스(Experimental Example 3: Cutibacterium acnes of the composite ( Cutibacterium acnes)Cutibacterium acnes) 에 대한 항균 활성 확인Confirmation of antibacterial activity against
각 샘플의 최소저해농도 (Minimum Inhibition Concentration: MIC)를 측정하기 위한 실험을 수행하였다. 구체적으로, 24시간 동안 배양한 큐티 박테리움 아크네스(Cutibacterium acnes)를 3 ml RCM 배지에 넣고, 동시에 샘플을 농도별로 각각 첨가한 후 혐기조건하에서 37℃에서 24시간 동안 배양하였다. 카페산의 MIC를 측정하기 위하여 2배 계열 희석법(two-fold serial dilution method)을 사용하였다. 여기서 MIC는 미생물의 성장을 억제하는 최소 농도로 정의한다. 그 결과를 하기 표 8과 표 9에 나타내었다.An experiment was performed to measure the Minimum Inhibition Concentration (MIC) of each sample. Specifically, Cutibacterium acnes cultured for 24 hours was placed in 3 ml RCM medium, and samples were added at each concentration at the same time, followed by incubation at 37° C. for 24 hours under anaerobic conditions. To measure the MIC of caffeic acid, a two-fold serial dilution method was used. Here, MIC is defined as the minimum concentration that inhibits the growth of microorganisms. The results are shown in Tables 8 and 9 below.
상기 표 8, 표 9에 나타난 바와 같이, 얌빈뿌리, 연꽃뿌리, 마시멜로뿌리, 질경이씨 및 타마린드씨 유래 뮤신 단일 조성보다 복합 추출물 처리시 여드름 균주에 대한 강한 향균력을 나타내는 것을 확인하였다. 실시예 2-1 내지 2-4의 샘플은 모두 비교예 1 내지 8 대비 P. acnes에 대한 향균력이 현저히 향상되는 것으로 나타났으며, 특히 실시예 2-2 내지 2-4의 샘플은 C. acnes에 대한 향균력이 현저히 높게 나타났다.As shown in Tables 8 and 9, it was confirmed that yambean root, lotus root, marshmallow root, plantain seed, and tamarind seed-derived mucin showed stronger antibacterial activity against acne strains when treated with the complex extract than a single composition. All of the samples of Examples 2-1 to 2-4 showed significantly improved antibacterial activity against P. acnes compared to Comparative Examples 1 to 8, and in particular, the samples of Examples 2-2 to 2-4 showed a marked improvement in antibacterial activity against C. acnes . The antibacterial activity was remarkably high.
이상에서 살펴본 바와 같이, 일 양상의 구체적인 실시예를 상세하게 설명되었으나, 일 양상의 사상을 이해하는 당업자는 동일한 사상의 범위 내에서 다른 구성요소를 추가, 변경, 삭제를 통하여, 퇴보적인 다른 발명이나 일 양상 사상의 범위 내에 포함되는 다른 실시예를 용이하게 제안할 수 있을 것이다. 그러므로 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며 한정적이 아닌 것으로 이해해야만 한다. 일 양상의 범위는 상술한 상세한 설명보다는 후술하는 특허청구의 범위에 의하여 나타내어지며, 특허청구의 범위의 의미 및 범위 그리고 그 균등 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 일 양상의 범위에 포함되는 것으로 해석되어야 한다.As reviewed above, the specific embodiment of one aspect has been described in detail, but those skilled in the art who understand the idea of one aspect may add, change, or delete other components within the scope of the same idea, thereby degenerate other inventions or Other embodiments may readily be suggested that fall within the scope of an aspect idea. Therefore, the embodiments described above should be understood as illustrative in all respects and not limiting. The scope of one aspect is indicated by the scope of the following claims rather than the above-described detailed description, and all changes or modifications derived from the meaning and scope of the claims and equivalent concepts thereof are included in the scope of one aspect. should be interpreted as
Claims (10)
i) 얌빈뿌리 유래 뮤신, 연꽃뿌리 유래 뮤신, 마시멜로뿌리 유래 뮤신, 질경이씨 유래 뮤신 및 타마린드씨 유래 뮤신; 및
ii) 뮤신을 각각 함유하는 얌빈뿌리 추출물, 연꽃뿌리 추출물, 마시멜로뿌리 추출물, 질경이씨 추출물 및 타마린드씨 추출물. A cosmetic composition for improving skin conditions comprising the following i) or ii) components;
i) mucin derived from yambean root, mucin derived from lotus root, mucin derived from marshmallow root, mucin derived from plantain seed, and mucin derived from tamarind seed; and
ii) Yambin root extract, lotus root extract, marshmallow root extract, plantain seed extract and tamarind seed extract each containing mucin.
i) 얌빈뿌리 유래 뮤신, 연꽃뿌리 유래 뮤신, 마시멜로뿌리 유래 뮤신, 질경이씨 유래 뮤신 및 타마린드씨 유래 뮤신; 및
ii) 뮤신을 각각 함유하는 얌빈뿌리 추출물, 연꽃뿌리 추출물, 마시멜로뿌리 추출물, 질경이씨 추출물 및 타마린드씨 추출물.
A pharmaceutical composition for the prevention or treatment of inflammatory skin diseases, acne, or skin infections caused by P. acnes, comprising the following i) or ii);
i) mucin derived from yambean root, mucin derived from lotus root, mucin derived from marshmallow root, mucin derived from plantain seed, and mucin derived from tamarind seed; and
ii) Yambin root extract, lotus root extract, marshmallow root extract, plantain seed extract and tamarind seed extract each containing mucin.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220113487A KR102542555B1 (en) | 2022-09-07 | 2022-09-07 | Cosmetic composition for anti-inflammatory and anti-acne comprising vegetable mucin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220113487A KR102542555B1 (en) | 2022-09-07 | 2022-09-07 | Cosmetic composition for anti-inflammatory and anti-acne comprising vegetable mucin |
Publications (1)
Publication Number | Publication Date |
---|---|
KR102542555B1 true KR102542555B1 (en) | 2023-06-15 |
Family
ID=86763541
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020220113487A Active KR102542555B1 (en) | 2022-09-07 | 2022-09-07 | Cosmetic composition for anti-inflammatory and anti-acne comprising vegetable mucin |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102542555B1 (en) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002094722A1 (en) * | 2001-05-22 | 2002-11-28 | Biss-Biosystems Aps | Flocculant derived from a vegetable source and method for flocculation |
KR20030006856A (en) * | 2001-07-16 | 2003-01-23 | 이충우 | Inhibitor of acne microbe's growth |
WO2003075678A1 (en) * | 2002-03-12 | 2003-09-18 | Mars Incorporated | Food product for treatment of animal hairballs |
KR20050028565A (en) * | 2003-09-18 | 2005-03-23 | 주식회사 태평양 | A composition containing plantago asiatica linne extract for skin external application |
KR20130047806A (en) * | 2011-10-31 | 2013-05-09 | (주)아모레퍼시픽 | Skin external composition containing phytomucin |
KR101458887B1 (en) * | 2014-07-09 | 2014-11-12 | 씨앤텍 주식회사 | Composition for improving skin condition containing the complex extracts of Pachyrhizus erosus, Brassica oleracea L. var botrytis, Malva sinensis var. mauritiana Mill. and Cetraria islandica |
KR20170038500A (en) * | 2015-09-30 | 2017-04-07 | (주)아모레퍼시픽 | Cosmetic composition comprsing extract mucin |
KR20170072052A (en) * | 2015-12-16 | 2017-06-26 | 경상북도(농업기술원생물자원연구소장) | An antibacterial composition comprising the pachyrhizus erosus root bark extract as an effective component |
KR20190021114A (en) * | 2017-08-22 | 2019-03-05 | 유한킴벌리 주식회사 | Composition for anti-inflammation, inhibiting secretion of sebum, or treating acne on the skin comprising plant extract |
-
2022
- 2022-09-07 KR KR1020220113487A patent/KR102542555B1/en active Active
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002094722A1 (en) * | 2001-05-22 | 2002-11-28 | Biss-Biosystems Aps | Flocculant derived from a vegetable source and method for flocculation |
EP1417154A2 (en) * | 2001-05-22 | 2004-05-12 | Biss-Biosystems APS c/o George Mhlanga | Flocculant derived from a vegetable source and method for flocculation |
KR20030006856A (en) * | 2001-07-16 | 2003-01-23 | 이충우 | Inhibitor of acne microbe's growth |
WO2003075678A1 (en) * | 2002-03-12 | 2003-09-18 | Mars Incorporated | Food product for treatment of animal hairballs |
KR20050028565A (en) * | 2003-09-18 | 2005-03-23 | 주식회사 태평양 | A composition containing plantago asiatica linne extract for skin external application |
KR20130047806A (en) * | 2011-10-31 | 2013-05-09 | (주)아모레퍼시픽 | Skin external composition containing phytomucin |
KR101458887B1 (en) * | 2014-07-09 | 2014-11-12 | 씨앤텍 주식회사 | Composition for improving skin condition containing the complex extracts of Pachyrhizus erosus, Brassica oleracea L. var botrytis, Malva sinensis var. mauritiana Mill. and Cetraria islandica |
KR20170038500A (en) * | 2015-09-30 | 2017-04-07 | (주)아모레퍼시픽 | Cosmetic composition comprsing extract mucin |
KR20170072052A (en) * | 2015-12-16 | 2017-06-26 | 경상북도(농업기술원생물자원연구소장) | An antibacterial composition comprising the pachyrhizus erosus root bark extract as an effective component |
KR20190021114A (en) * | 2017-08-22 | 2019-03-05 | 유한킴벌리 주식회사 | Composition for anti-inflammation, inhibiting secretion of sebum, or treating acne on the skin comprising plant extract |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USRE46788E1 (en) | Parthenolide free bioactive ingredients from feverfew (Tanacetum parthenium) and processes for their production | |
KR101146206B1 (en) | Cosmetic Composition And Composition of Skin External Application | |
KR101841181B1 (en) | Toothpaste composition comprising herval extract | |
JP2003192605A (en) | Lipase inhibitant | |
Yampolsky et al. | Sea buckthorn (lat. Hippophaë) | |
KR102150927B1 (en) | Cosmetic and pharmaceutical compositin comprising sasa quelpaertensis extract and urea | |
KR101930264B1 (en) | Cosmetic composition for inhibiting secretion of sebum and for improving acne symptoms containing natural complex extract | |
KR101822092B1 (en) | Cosmetic composition for preventing thermal skin aging containing aloe vera leaves complex extract | |
KR102594674B1 (en) | Oral composition comprising herbal complex | |
KR101797526B1 (en) | Hair cosmetic composition containing an extract of Dendropanax morbifera ferment | |
JP2022167197A (en) | Hyaluronic Acid Production Promoter, Epidermal Hyaluronic Acid Production Promoter, and Dermal Hyaluronic Acid Production Promoter | |
KR102542555B1 (en) | Cosmetic composition for anti-inflammatory and anti-acne comprising vegetable mucin | |
KR20200142768A (en) | Composition for hangover cure conprising oriental herbal extract | |
CN115429725B (en) | Cosmetic composition for antioxidation, anti-inflammatory and skin tranquilization | |
KR20210048021A (en) | Antibacterial compositions comprising the citrus aurantium sinensis peel extract, the magnolia officinalis bark extract and polylysine | |
KR102488821B1 (en) | Manufacturing method of tee-tree extract and antimicrobial compositon comprising the same | |
US20140370136A1 (en) | Fermented pomegranate oil composition and method of preparing the same | |
Upadhyay | Nutritional, therapeutic, and pharmaceutical potential of Hibiscus species | |
KR101070469B1 (en) | Composition effective for alleviating atopic dermatitis | |
KR20160068215A (en) | Cosmetic Compositions Including a Natural Extract for Improvement of Acne | |
EA021203B1 (en) | Cinnamon- and basil-based composition for treating or preventing urinary infections and method for manufacture thereof | |
KR102176983B1 (en) | Method of manufacturing cosmetic composition for acnes improvement and cosmetic composition for acnes improvement produced by the same | |
KR20220132262A (en) | A Method for Preparing Liquid Eyelash Nutritional Supplements Containing a Large Amount of Black Beans and, the Liquid Nutritional Supplements for Eyelashes That is Produced through the Method | |
KR20170065187A (en) | Cosmetic composition for improving acne containing tea-tree leaves complex extract | |
AU2013201510B2 (en) | Parthenolide Free Bioactive Ingredients from Feverfew (Tanacetum Parthenium) and Processes for their Production |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20220907 |
|
PA0201 | Request for examination | ||
PA0302 | Request for accelerated examination |
Patent event date: 20220907 Patent event code: PA03022R01D Comment text: Request for Accelerated Examination |
|
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20221123 Patent event code: PE09021S01D |
|
E90F | Notification of reason for final refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Final Notice of Reason for Refusal Patent event date: 20230419 Patent event code: PE09021S02D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20230522 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20230607 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20230608 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration |